Observational, multicentre, retrospective study on patients taken care according to the national guidelines. The objective is to define, after the diagnosis confirmation, the frequency of PD-L1 expression in patients with large-cell lung neuroendocrine carcinoma (NEC), whatever the stage of the disease, and to correlate this parameter to clinical data at the time of diagnosis, therapeutic response and survival. Large-cell NECs present a bad prognostic and there is no evidence of treatment for these patients with advanced disease in second ligne of treatment at that time. To demonstrate the PD-L1 expression in this type of cancer might have a major therapeutic impact in a close future to access immunotherapies.
Study Type
OBSERVATIONAL
Enrollment
86
The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.
Centre Hospitalier D Argenteuil
Argenteuil, VAL D'oise, France
Site 12
Aix-en-Provence, France
Centre Hospitalier Universitaire
Angers, France
Site 05
Bastia, France
Site 22
Beauvais, France
Centre Hospitalier du Morvan
Brest, France
Site 43
Caen, France
Site 48
Clermont-Ferrand, France
Site 33
Créteil, France
Site 32
Elbeuf, France
...and 18 more locations
Frequency of PD-L1 expression in patients with large-cell neuroendocrine carcinoma (NEC)
Determine the frequency of PD-L1 expression in patients with large-cell neuroendocrine carcinoma (NEC)in terms of percentage of tumor cells expressing PD-L1 in immunohistochemistry (IHC) at the time of diagnosis: The frequency of PD-L1 expression determined by IHC will be as follow: * Negative PD-L1 tumours (\<1% of positive tumour cells) * Positive PD-L1 tumours (\> or = to 1% of positive tumour cells) * Low positive PD-L1 tumours (from 1% to 49% of positive tumour cells expressed) * High positive PD-L1 tumours (\> or = 50% of positive tumour cells expressed)
Time frame: Retrospective central evaluation on tumour materials (slides) collected on patients diagnosed with NEC between 01 January 2014 and 31 December 2016
Correlation of PD-L1 expression of tumour cells with clinical data
Describe the disease at the time of diagnosis using TNM IASLC/UICC 2009 classification
Time frame: Retrospective-data collected on patients diagnosed with NEC between 01 January 2014 and 31 December 2016
Objective Response Rate (ORR)
Objective Response Rate (ORR): best overall response of complete response (CR) or partial response (PR) to a first line of treatment using RECIST 1.1 criteria as assessed locally
Time frame: Retrospective-data collected on patients diagnosed with NEC between 01 January 2014 and 31 December 2016
Progression-free survival (PFS)
PFS of the first line of treatment using RECIST 1.1 criteria assessed locally defined as the time from first treatment start to disease progression or death for any cause expressed in months
Time frame: Retrospective-data collected on patients diagnosed with NEC between 01 January 2014 and 31 December 2016
Overall survival (OS)
OS defined as the time from first treatment start to death for any cause expressed in months
Time frame: Retrospective-data collected on patients diagnosed with NEC between 01 January 2014 and 31 December 2016
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.